Watch MNPR. Know when insiders buy.
One email the day a filing lands. Free.
Work order
64
WATCH · insiders 27, shorts 100
Insiders, 90 days
−$807K
net selling · 0 buys, 9 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $789.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$17.8MNET CASH —52W 41.48 – 123.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$6.6M | −$5.3M | — | -0.62 | −$3.2M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | $0 | — | — | −$5.2M | −$3.9M | — | -0.46 | −$3.5M | — | — | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$6.2M | −$5.2M | — | -0.64 | −$3.4M | — | — | Mar 27 |
| Q3 2025 · Sep 30 | — | — | — | −$4.1M | −$3.4M | — | -0.48 | −$2.1M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$3.2M | −$2.5M | — | -0.35 | −$1.1M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$3.2M | −$2.6M | — | -0.38 | −$5.7M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$11.1M | −$10.9M | — | -2.75 | −$2M | — | — | Mar 27 |
| Q3 2024 · Sep 30 | — | — | — | −$1.6M | −$1.3M | — | -0.37 | −$1.1M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$1.8M | −$1.7M | — | -0.49 | −$1.7M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$1.7M | −$1.6M | — | -0.51 | −$1.7M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.9M | −$1.8M | — | -0.61 | −$1.5M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$2.1M | −$2M | — | -0.69 | −$1.9M | — | — | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$16.7M | −$13.7M | — | -1.85 | −$12.2M | — | — | $35M | — |
| FY2024 · to Dec 31 | $0 | — | −$16.2M | −$15.6M | — | -4.11 | −$6.4M | — | — | $0 | — |
| FY2023 · to Dec 31 | — | — | −$8.8M | −$8.4M | — | -3.04 | −$7.9M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$10.5M | −$10.5M | — | -0.83 | −$7.2M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$9.1M | −$9.1M | — | -0.73 | −$7.3M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$6.5M | −$6.3M | — | -0.58 | −$4.7M | — | — | — | — |
Every number comes from Monopar Therapeutics's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.